Gland Pharma Limited
Our verdict
Financial trend (92/100) does the heavy lifting; valuation (40/100) is the drag.
Our fair value
Overvalued by 21%Buy-below (20% margin of safety): ₹2,086.59
Gland Pharma Limited earns a Buy from TickerMagic, with a blended score of 70/100. At ₹3,292.9 it trades above our blended DCF and relative-multiples fair value of ₹2,608.24, about 21% downside to that estimate — we read it as overvalued by 21%. On 37.4x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. It's trading right at its 52-week high of ₹3,385.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9. The average analyst target of ₹2,189.57 implies about 34% downside across 14 analysts. It clears 10 of 13 investability checks, with durability 75, valuation 65 and momentum 84 on our 0–100 scales.
Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,086.59.
Analyst views
1-year price
EOD · 2026-11-2052-week range
-2.75% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy70Piotroski F-score 8/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 10.5%
- Pass: Low debt (D/E < 0.5): 0.03x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 22%
- Pass: Earnings growing: 96%
- Pass: Net margin ≥ 10%: 16.0%
- Pass: Current ratio > 1.5: 4.68
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 12.58
- Pass: Piotroski ≥ 7: 8/9
Quarterly results
Annual financials
Shareholding
- Promoter51.8%
- Institutions36.3%
- Public & other11.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (16.0%).
- Trading near its 52-week high.
- Financially solid — Altman Z 12.58.
- High Piotroski quality score (8/9).
Opportunities
- Earnings growing (96% YoY).
- Revenue growing (22% YoY).
- Trading in our value buy zone versus sector peers.
Bear case
Threats
- Trades ~21% above our estimated fair value.
About Gland Pharma Limited
Gland Pharma Limited manufactures and sells injectable formulations globally, including in India, the United States, Europe, Canada, Australia, and New Zealand. The company develops active pharmaceutical ingredients through synthesis of complex molecules such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic compounds for various therapeutic categories.
Gland Pharma Limited — frequently asked questions
Is Gland Pharma Limited a buy, hold or sell?
TickerMagic currently rates Gland Pharma Limited (GLAND) a Buy, based on a blended score of 70/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Gland Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates Gland Pharma Limited's fair value at about ₹2,608.24, versus a current price of ₹3,292.9 — roughly 21% downside. On that basis the stock looks overvalued by 21%.
Is Gland Pharma Limited financially healthy?
Gland Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9.
How has Gland Pharma Limited's share price performed?
Gland Pharma Limited is up 15% over three months, and last traded at ₹3,292.9. Past performance doesn't predict future returns.
More in Healthcare
Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.